Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» cholangiocarcinoma
cholangiocarcinoma
ESMO: Relay spotlights expanded FGFR2 inhibitor data it hopes will pave accelerated approval
ESMO: Relay spotlights expanded FGFR2 inhibitor data it hopes will pave accelerated approval
Fierce Biotech
ESMO
Relay Therapeutics
RLY-4008
cholangiocarcinoma
Flag link:
Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Endpoints
Incyte
Pemazyre
pemigatinib
bile duct cancer
cholangiocarcinoma
FDA
Flag link:
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
Pharmaceutical Business Review
FDA
Incyte
priority review
pemigatinib
cholangiocarcinoma
Flag link:
Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication
Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication
BioSpace
Agios Pharmaceuticals
Tibsovo
ivosidenib
clinical trials
cholangiocarcinoma
Flag link:
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
CP Wire
Sriaomics
STP705
cholangiocarcinoma
hepatocellular carcinoma
RNAi
Flag link:
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
Sriaomics
STP705
cholangiocarcinoma
hepatocellular carcinoma
Flag link:
Imbrium Therapeutics and Mundipharma EDO Announce Orphan Drug Designation for Relapsed Refractory Biliary Tract Cancer Treatment
Imbrium Therapeutics and Mundipharma EDO Announce Orphan Drug Designation for Relapsed Refractory Biliary Tract Cancer Treatment
CP Wire
Imbrium Therapeutics
Mundipharma EDO
Purdue Pharma
etoposide toniribate
cholangiocarcinoma
Flag link:
Imbrium Therapeutics and Mundipharma EDO Announce Orphan Drug Designation for Relapsed Refractory Biliary Tract Cancer Treatment
Imbrium Therapeutics
Mundipharma EDO
Purdue Pharma
etoposide toniribate
cholangiocarcinoma
Flag link: